A Look At Niagen Bioscience (NAGE) Valuation After Q1 2026 Beat And Niagen Plus Telehealth Launch
Niagen Bioscience (NAGE) is back on investors’ radar after reporting Q1 2026 results that exceeded consensus estimates, alongside the launch of its Niagen Plus telehealth platform and at-home prescription injection kits.
See our latest analysis for Niagen Bioscience.
Despite the upbeat Q1 report and new Niagen Plus initiatives, the stock’s recent momentum has been weak, with a 30 day share price return of a 6.26% decline and a year to date share price return of a 32.96% decline. The 3 year total shareholder return also remains very large relative to its 1 year total shareholder return of a 54.65% decline.
If Niagen’s telehealth push has caught your attention, it may be a good moment to see what else is happening across fast growing healthcare and wellness tech, starting with 35 healthcare AI stocks.
With Q1 earnings ahead of expectations, new Niagen Plus products rolling out, and the stock showing a very large 3 year total return versus a 54.65% 1 year decline, is this a mispriced opportunity, or is future growth already reflected in today’s valuation?
Most Popular Narrative: 69.2% Undervalued
Niagen Bioscience's most followed narrative places fair value at $13.60 per share, versus a last close of $4.19, which sets up a wide valuation gap for investors to assess.
Expansion into the pharmaceutical-grade Niagen ingredient market, including the launch of Niagen IV and injections at clinics, is expected to drive future revenue growth due to increasing demand and the anticipated resolution of supply chain issues.
Want to see what underpins that gap between current price and fair value? The narrative leans heavily on faster top line growth, fatter margins, and a richer future earnings multiple. Curious how those moving parts combine into that $13.60 figure and a required return baked in at a single discount rate? The full breakdown joins those pieces together in a way the headline numbers alone do not.
Result: Fair Value of $13.60 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, that upside view still leans on smooth regulatory outcomes and dependable supply for pharmaceutical grade Niagen. Both of these factors could disappoint and challenge the thesis.
Find out about the key risks to this Niagen Bioscience narrative.
Next Steps
With the story pulling in both strong upside potential and clear risk flags, it helps to move quickly and review the evidence yourself through the 3 key rewards and 1 important warning sign.
Looking for more investment ideas?
If Niagen Bioscience has sharpened your focus, do not stop here. Broaden your watchlist now so you do not miss other compelling setups taking shape.
- Spot potential turnaround stories early by scanning 25 elite penny stocks with strong financials that already show healthier fundamentals than most tiny stocks.
- Hunt for quality at a reasonable entry point with the 51 high quality undervalued stocks that filters for strong businesses trading below their estimated worth.
- Prioritize resilience by reviewing the 72 resilient stocks with low risk scores tailored to highlight companies with more stable profiles and fewer red flags.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com